Ind Swift Laboratories Ltd Stock Price Today (NSE: INDSWFTLAB)
Fundamental Score
Ind Swift Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ind Swift Laboratories Ltd share price today is ₹228.63, up +4.01% on NSE/BSE as of 3 August 2026. Ind Swift Laboratories Ltd (INDSWFTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.99K (Cr). The 52-week high for INDSWFTLAB share price is ₹248.45 and the 52-week low is ₹87.15. At a P/E ratio of 40.13x, INDSWFTLAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 3.87% and a debt-to-equity ratio of 0.01.
Ind Swift Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Ind Swift Laboratories Ltd share price chart: 11.73% return over the past month. 52-week high ₹248.45, 52-week low ₹87.15.
Ind Swift Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹220.79 | ₹227.30 | ₹215.00 | ₹224.27 | 4.46L (Cr) | |
| ₹226.00 | ₹228.00 | ₹216.70 | ₹219.82 | 3.70L (Cr) | |
| ₹238.00 | ₹238.00 | ₹220.00 | ₹223.58 | 7.45L (Cr) | |
| ₹242.00 | ₹242.00 | ₹235.00 | ₹236.31 | 3.92L (Cr) | |
| ₹228.00 | ₹240.70 | ₹228.00 | ₹239.91 | 4.79L (Cr) | |
| ₹225.02 | ₹229.99 | ₹217.77 | ₹227.49 | 4.47L (Cr) | |
| ₹232.98 | ₹236.95 | ₹225.00 | ₹225.99 | 3.97L (Cr) | |
| ₹235.72 | ₹240.00 | ₹230.63 | ₹237.60 | 2.71L (Cr) | |
| ₹227.02 | ₹238.30 | ₹227.02 | ₹233.99 | 4.38L (Cr) | |
| ₹231.40 | ₹233.95 | ₹227.01 | ₹231.47 | 2.89L (Cr) |
Ind Swift Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹203.95 | ₹248.45 | ₹197.10 | ₹224.27 | +9.96% | |
| ₹154.00 | ₹211.00 | ₹152.80 | ₹203.53 | +32.16% | |
| ₹138.11 | ₹161.00 | ₹129.31 | ₹152.11 | +10.14% | |
| ₹135.00 | ₹156.80 | ₹127.30 | ₹137.54 | +1.88% | |
| ₹138.00 | ₹151.51 | ₹126.00 | ₹131.43 | -4.76% | |
| ₹112.90 | ₹151.98 | ₹106.23 | ₹145.33 | +28.72% | |
| ₹89.24 | ₹117.80 | ₹87.25 | ₹113.41 | +27.08% | |
| ₹97.00 | ₹99.50 | ₹87.15 | ₹88.15 | -9.12% | |
| ₹102.71 | ₹106.50 | ₹93.00 | ₹97.48 | -5.09% | |
| ₹97.20 | ₹112.50 | ₹94.00 | ₹102.71 | +5.67% | |
| ₹97.00 | ₹112.70 | ₹94.71 | ₹95.23 | -1.82% | |
| ₹106.67 | ₹110.00 | ₹92.70 | ₹96.06 | -9.95% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ind Swift Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ind Swift Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDSWFTLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Revenue Growth (22.82%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (66.22% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (77.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (43.89x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (3.87%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.70%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 40.13x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-6.37% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-93.03 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ind Swift Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ind Swift Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ind Swift Laboratories LtdInd Swift Labor...Selected✓ INDSWFTLAB • 532305 | 49.4/100 | ₹228.63₹229 | ₹1985.51₹1985.51 | 40.13Average 40.1 Average | 3.87%Poor 3.87% Poor | 4.70%Poor 4.70% Poor | 0.01Excellent 0.0 Excellent | 77.68%Excellent 77.68% Excellent | -6.37%Poor -6.37% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Ind Swift Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for INDSWFTLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹71.24 | ₹108.57 | 1.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ind Swift Laboratories Ltd Quarterly Performance
Latest quarterly metrics for INDSWFTLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
22.82%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.35%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-6.37%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
77.68%
Compounded annual net profit growth over 5 years
Ind Swift Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDSWFTLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ind Swift Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ind Swift Laboratories Ltd (INDSWFTLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ind Swift Laboratories Ltd
About INDSWFTLAB (Ind Swift Laboratories Ltd)
Ind Swift Laboratories Ltd is a dynamic pharmaceutical entity carving its niche in the global healthcare landscape. With a steadfast commitment to innovation and quality, the compa...ny dedicates its resources to the research, development, and production of a diverse portfolio of pharmaceutical products. Its activities are deeply rooted in scientific rigor, with a focus on creating effective and accessible medications for a range of therapeutic needs. By combining advanced technologies and skilled personnel, Ind Swift Laboratories strives to address pressing health challenges and improve patient outcomes worldwide. The company stands as a testament to the power of dedicated pharmaceutical research in improving global health. The core business of Ind Swift Laboratories revolves around the creation of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished formulations, contributing to a comprehensive approach to drug development and manufacturing. The company strategically markets these products both domestically and internationally, reaching healthcare providers and patients across different regions. They have a strong emphasis on the manufacturing process, as the creation of APIs requires the utmost control. They're committed to high quality ingredients to ensure the safety and efficacy of its medicinal products. Ind Swift Laboratories is not just producing pharmaceuticals, but rather, is actively contributing to global healthcare solutions through its expanded reach and market strategy. Ind Swift Laboratories' dedication goes beyond simple manufacturing; they operate as an innovative force, pushing the boundaries of pharmaceutical science. This commitment is evident in its expanding portfolio of APIs, which caters to a broad spectrum of therapeutic areas. This includes treatments for cardiovascular conditions, diabetes, and a host of other ailments, demonstrating its commitment to addressing a wide range of health concerns. Through tireless effort and a focus on continuous improvement, Ind Swift Laboratories seeks to develop novel solutions that contribute to a healthier future. This dedication to improving the lives of individuals through innovative pharmaceuticals is the driving force behind Ind Swift Laboratories' growth and success.
Company Details
Key Leadership
Corporate Events
INDSWFTLAB Share Price: Frequently Asked Questions
What is the current share price of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd (INDSWFTLAB) trades at ₹228.63 on NSE and BSE. Market cap ₹1.99K (Cr). Educational data only.
What is the P/E ratio of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has a P/E of 40.13x vs industry average 34.89x.
What is the Bull Run score for Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has a Bull Run score of 49.4/100 based on 25+ financial parameters.
Does Ind Swift Laboratories Ltd pay dividends?
Ind Swift Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has ROE of 3.87%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ind Swift Laboratories Ltd?
Ind Swift Laboratories Ltd has debt-to-equity of 0.01.
Is Ind Swift Laboratories Ltd a good investment?
Bull Run gives Ind Swift Laboratories Ltd a score of 49.4/100. This is not investment advice — consult a SEBI-registered advisor.